FDA’s interim peptide access policy reaches White House review
Filed October 15, 2026. What the listing says, what is reported, and what it changes today.
On October 14, 2026, the White House Office of Information and Regulatory Affairs received an FDA notice titled “Interim Access Policy for Compounding Using Certain Peptides” (RIN 0910-ZD94). It is not in effect, its text is not public, and BPC-157 remains without a lawful 503A compounding route.
The OIRA review list, run October 15, gives only the title, the stage (“notice”) and that it is not economically significant. The Associated Press, citing two people familiar with the plan, reports that it would let pharmacies temporarily compound some popular peptides, including BPC-157, under enforcement discretion. The Washington Post and Pink Sheet report that FDA career staff oppose it; we could not read either article in full.
What it means for patients: nothing changes until FDA publishes the notice. When it does, read which peptides, which uses and which quality conditions it names. Enforcement discretion is not approval, and FDA’s own safety-risks table still says it cannot judge whether compounded BPC-157 causes harm.
Background: FDA moved BPC-157 out of Category 2 in April after its nomination was withdrawn, and its advisory committee voted 8–6 in July to recommend it for ulcerative colitis. The full timeline is in our October status report; prices that clinics already charge are in our peptide price read.
Sources: OIRA rules under review (read Oct 15, 2026); STAT/AP, Oct 15, 2026. Confidence: listing confirmed; contents reported.